[Virtual Presenter] Bochéry and Dallah Healthcare are pleased to present this strategic partnership opportunity. We are eager to discuss how our cutting-edge healthcare solutions can positively impact the Kingdom of Saudi Arabia market. Let us now delve into the specifics.. 

Scene 1

Strategic Partnership Opportunity: Bochéry & Dallah Healthcare

LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h in the KSA Market

[Audio] The population of Saudi Arabia is approximately 34 million people, with a growing demand for healthcare services. This demographic trend presents a significant opportunity for pharmaceutical companies like ours to expand their presence in the region. With a large and young population, there is a pressing need for innovative solutions to address the rising incidence of chronic diseases such as diabetes.. 

Scene 2

Objective The Population of Saudi Arabia Diabetes and Diabetic Foot Statistics in Saudi Arabia Diabetic Foot Ulcers (DFU) and Amputation in Saudi Arabia Pharmaceutical Market in Saudi Arabia Market Opportunity in KSA Partnership Setup

[Audio] The objective of this partnership is clear: to form a strategic alliance between Bochéry and Dallah Healthcare to bring innovative healthcare solutions to the Kingdom of Saudi Arabia. By combining our strengths, we aim to address the unmet needs in diabetic foot ulcer care and diabetes monitoring. Our ultimate goal is to establish a successful partnership that delivers cutting-edge diabetic care solutions to the KSA market, leveraging Dallah's local expertise and Bochéry's advanced healthcare products. 

Scene 3

To form a strategic partnership between Bochéry and Dallah Healthcare to introduce innovative healthcare solutions in KSA.

Leverage Dallah’s market reach and Bochéry's innovative solutions to address unmet needs in diabetic foot ulcer (DFU) care and diabetes monitoring.

Our  goal of establishing a strategic partnership with Dallah Healthcare to deliver innovative diabetic care solutions to the KSA market, utilizing Dallah's local expertise and Bochéry's advanced healthcare products.

[Audio] The population of Saudi Arabia has consistently grown over the years, reaching approximately 34 million people as of 2024. Advancements in healthcare, a younger demographic structure, and the influx of foreign workers drawn by the country's expanding economic opportunities under Saudi Vision 2030 contributed to this growth.. 

Scene 4

As of 2024, the population of Saudi Arabia is approximately 34 million people. This figure reflects consistent growth influenced by factors such as improved healthcare, a younger demographic structure, and the influx of expatriate workers due to expanding economic opportunities under Saudi Vision 2030​
 General Authority for Statistics Saudi Arabia Today Saudi Press Agency

[Audio] Saudi Arabia has a large population of approximately 34 million people, with over 18% of them suffering from diabetes. This translates to around 6.12 million individuals living with diabetes. Furthermore, it's estimated that between 15% to 25% of these diabetic patients develop diabetic foot ulcers, resulting in a minimum of 918000 to a maximum of 1,530000 individuals affected. On average, this would mean that around 1.22 million people suffer from diabetic foot ulcers.. 

Scene 5

Diabetes and Diabetic Foot Statistics in Saudi Arabia

- Population in Saudi Arabia: Approximately 34 million - Diabetes prevalence: Over 18% of the population - Number of diabetic patients: Approximately 6,120,000
 - Diabetic foot prevalence among diabetic patients: 15% to 25%   * Minimum number of diabetic foot patients (15%): 918,000   * Maximum number of diabetic foot patients (25%): 1,530,000   * Average number of diabetic foot patients: 1,224,000

[Audio] In Saudi Arabia, it's estimated that approximately 6.5 million individuals will have diabetes by 2024. This staggering figure is expected to rise to 8 million by 2029, driven by population growth and aging. Unfortunately, this surge in diabetes cases comes with a significant risk of Diabetic Foot Ulcers (DFU), which can lead to amputations. In fact, it's predicted that there will be a 20% increase in amputations over the next five years. This alarming trend highlights the urgent need for effective solutions to prevent and treat DFU.. 

Scene 6

Diabetic Foot Ulcers (DFU) and Amputation in Saudi Arabia

Analysis of Risks, Amputation Rates, and Future Prevalence (2024-2029)

[Audio] The risks associated with diabetic foot ulcers are quite alarming. Between 15 and 25 percent of individuals with diabetes will develop these ulcers during their lifetime, highlighting the importance of prevention and early detection. The main risk factors include neuropathy, poor glycemic control, peripheral arterial disease, and a history of previous foot ulcers, which can significantly increase the likelihood of developing a DFU. The mortality rate for patients with DFUs is approximately 18.5%, nearly double that of patients without DFUs, and amputations can lead to even higher mortality rates, reaching as high as 32.2%.. 

Scene 7

• DFU Prevalence: 15-25% of individuals with diabetes develop DFUs during their lifetime. • Main Risk Factors:   - Neuropathy (loss of sensation in the feet).   - Poor glycemic control.   - Peripheral arterial disease.   - History of previous foot ulcers. • Impact on Mortality:   - Mortality rate for patients with DFUs: 18.5%, almost twice that of patients without DFUs.   - Amputations lead to even higher mortality rates (32.2%).

[Audio] In Saudi Arabia, it is estimated that between five percent to fifteen percent of diabetic patients with diabetic foot ulcers may require amputations. This translates to over three thousand diabetic-related amputations occurring annually. Furthermore, the data shows that men are disproportionately affected, with amputation and mortality rates significantly higher among males, ranging from seventy-six percent to seventy-eight percent.. 

Scene 8

• Annual Amputation Rates:   - 5-15% of diabetic patients with DFUs may require amputations.   - Over 3,000 diabetic-related amputations occur annually. • Gender Impact:   - Amputation and mortality rates are significantly higher among males (76-78%).

[Audio] Approximately 6.5 million individuals will have diabetes in Saudi Arabia by 2024, according to the data. This number is expected to rise to 8 million by 2029. Moreover, the rate of diabetic foot ulcers is increasing proportionally. Additionally, the forecast estimates a 20% increase in amputations due to population growth and aging.. 

Scene 9

Prevalence and Forecast for the Next 5 Years

• 2024 Estimate:   - Approximately 6.5 million individuals with diabetes in Saudi Arabia.   - DFU rates are rising proportionally. • 2029 Forecast:   - Diabetes prevalence projected to rise to 8 million.   - Estimated increase in amputations by 20% due to population growth and aging.

[Audio] The risks associated with diabetic foot are numerous and can have significant consequences on a person's quality of life. Ulcers and wounds can develop due to poor circulation and increased infection risk, leading to delayed healing. This can also increase the risk of bacterial infections, which can spread quickly and affect bones and tissues. In advanced cases, amputation may be necessary to prevent the spread of infection. Moreover, the psychological and social impact of losing a limb can be devastating, affecting one's ability to maintain independence and participate in daily activities. Furthermore, the high costs associated with treating diabetic foot can place a significant burden on healthcare systems.. 

Scene 10

1. Ulcers and Wounds    - Delayed wound healing due to poor circulation and increased infection risk
 2. Bacterial Infections    - Can lead to severe inflammation affecting bones and tissues
 3. Amputation    - Advanced diabetic foot cases may require limb amputation to prevent infection spread
 4. Psychological and Social Impact    - Quality of life is affected due to loss of mobility and work capacity
 5. High Healthcare Costs    - Diabetic foot increases healthcare burden due to intensive treatments and surgeries

[Audio] The estimated healthcare costs for diabetic foot in Saudi Arabia are substantial. The annual treatment cost per patient ranges between SAR 40000 and SAR 80000. This translates into significant expenses when considering the total annual cost for all patients. For 918000 patients, the estimated cost would be approximately SAR 55 billion. Alternatively, with 1,530000 patients, the estimated cost would be around SAR 91.8 billion. On average, with 1,244000 patients, the estimated cost would be approximately SAR 73.4 billion.. 

Scene 11

Estimated Healthcare Costs for Diabetic Foot in Saudi Arabia

Annual Treatment Cost per Patient: Ranges between SAR 40,000 and SAR 80,000.

* Total Annual Cost for All Patients:
1- For 918,000 patients: Approximately SAR 55 billion.

2- For 1,530,000 patients: Approximately SAR 91.8 billion.
 3- For average 1,244,000 patients: Approximately
 SAR 73.4billion.

[Audio] The high costs associated with diabetic foot ulcer treatment can be attributed to several factors. Specialized medical teams are required to treat these complex conditions, which increases the overall cost. Advanced surgeries, including amputations, may be necessary in severe cases, contributing to the high expenses. Medical equipment such as prosthetics and physiotherapy tools are often needed, adding to the overall cost. Extended hospital stays are common due to the severity of the conditions, resulting in higher healthcare expenditures. Chronic complications like systemic infections can arise, leading to increased healthcare costs.. 

Scene 12

Specialized Medical Teams: Required for treating ulcers and infections. Advanced Surgeries: Including amputations in severe cases. Medical Equipment: Such as prosthetics and physiotherapy tools. Extended Hospital Stays: Due to the severity of conditions. Chronic Complications: Like systemic infections, which increase healthcare costs.

[Audio] Prevention is crucial in addressing the challenges posed by diabetic foot ulcers. Educating the public and at-risk individuals about the importance of proper foot care can prevent the onset of these debilitating conditions. Better management and monitoring of diabetic patients can help identify potential issues early on, thereby preventing the escalation of the disease. Detecting and managing mild cases promptly can also prevent the progression of the condition. Prioritizing prevention can reduce the burden of diabetic foot ulcers on individuals, families, and society as a whole.. 

Scene 13

Health Awareness Programs: To educate the public and at-risk individuals. Improved Foot Care for Diabetic Patients: Ensuring better management and monitoring. Early Detection and Management of Mild Cases: Preventing the escalation of the disease.

[Audio] In Saudi Arabia, there are numerous medical centers and hospitals providing diabetic foot care services. Over 500 government and private hospitals offer specialized services for diabetic foot patients. More than 50 specialized diabetes centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. Many hospitals also have specialized units or departments dedicated to diabetic foot care. Hundreds of outpatient clinics provide diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable facilities in this field include King Faisal Specialist Hospital & Research Center, National Guard Health Affairs Hospitals, Dallah Hospital Group, Dr. Sulaiman Al Habib Hospitals, and Diabetes Centers affiliated with the Ministry of Health across various regions.. 

Scene 14

Number of Medical Centers and Hospitals in Saudi Arabia Providing Diabetic Foot Care

Number of Medical Centers and Hospitals in Saudi Arabia Providing Diabetic Foot Care*The number of hospitals and medical centers in Saudi Arabia offering treatment and care for diabetic foot patients is growing due to the increasing prevalence of diabetes and diabetic foot complications. 

Based on healthcare statistics and reports:

Number of Relevant Centers and Hospitals:
*1. Hospitals: 
There are approximately 500 government and private hospitals in Saudi Arabia 
(based on Ministry of Health data and 2024 reports).   
- Many of these hospitals provide specialized services for diabetic foot care. 
2. Specialized Diabetes Centers:    More than 50 specialized centers-focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. 3. Specialized Units within Hospitals:   

 Many hospitals include specialized units or departments for diabetic foot care, especially in major hospitals such as National Guard hospitals, King Faisal Specialist Hospital, Dallah Hospital, and Dr. Sulaiman Al Habib Hospital. 4. Outpatient Clinics:   
Hundreds of outpatient clinics provide diabetic foot care services, including primary healthcare centers under the Ministry of Health.### *Notable Facilities in This Field:
1. King Faisal Specialist Hospital & Research Center.  
2. National Guard Health Affairs Hospitals.  
3. Dallah Hospital Group. 
4. Dr. Sulaiman Al Habib Hospitals.  
5. Diabetes Centers affiliated with the Ministry of Health across various regions 2,261 centers The number of primary healthcare centers affiliated with the Saudi Ministry of Health is 2,261 centers, according to recent statistics. These centers are distributed across the Kingdom to provide comprehensive healthcare services, including preventive, curative, and promotional care.
​ويكيبيديا، الموسوعة الحرة
وزارة الصحة السعودية

[Audio] The pharmaceutical market in Saudi Arabia has shown remarkable growth over the years, driven primarily by the country's large population and increasing awareness about health issues. The current market value stands at approximately 45 billion Saudi Riyals, with a projected annual growth rate of 8%. This presents a significant opportunity for companies looking to expand their presence in the region. In particular, the market for diabetes-related treatments has seen substantial growth, driven by the rising prevalence of diabetes among the local population. With over 6.12 million people affected by diabetes, Saudi Arabia ranks among the top countries globally in terms of diabetes prevalence. This trend is expected to continue, with the World Health Organization predicting a further increase in the number of diabetes cases in the coming years. As a result, there is a growing demand for innovative and effective treatments for diabetes, including devices such as continuous glucose monitors and wound care products. Companies that can provide these solutions will be well-positioned to capitalize on this growing market.. 

Scene 15

Analysis of the Current Market Value and Diabetes-related Treatments

[Audio] The pharmaceutical industry in Saudi Arabia has experienced significant growth over the past few years, with a current market value of SAR 44 billion, equivalent to USD 11.72 billion in 2022. This impressive figure is expected to continue growing, reaching SAR 56.6 billion, or approximately USD 15.09 billion, by 2027. With a compound annual growth rate of 5.2%, this market presents a promising opportunity for companies looking to expand their presence in the region.. 

Scene 16

The current market value of pharmaceuticals in Saudi Arabia: - SAR 44 billion (USD 11.72 billion) in 2022 - Expected to reach SAR 56.6 billion (USD 15.09 billion) by 2027 - CAGR “Compounded Annual Growth Rate “: 5.2%

[Audio] The companies involved in this strategic partnership opportunity are Jamjoom Pharma, Avalon Pharma, Tabuk Pharmaceuticals, and SPIMACO, which are prominent pharmaceutical organizations with a strong presence in the Kingdom of Saudi Arabia, focusing on providing high-quality treatments to patients.. 

Scene 17

Companies: - Jamjoom Pharma - Avalon Pharma - Tabuk Pharmaceuticals - SPIMACO (Saudi Pharmaceutical Industries)

[Audio] In the KSA market, notable competitors across various categories can be found. Key players in the area of DFU care include Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care, which offer products such as wound dressings and negative pressure wound therapy devices. Prominent competitors in the category of continuous glucose monitoring systems are Abbott with their Freestyle Libre product, Medtronic with their Guardian system, and Dexcom. Additionally, in the field of wound care plasters, major players like 3M Healthcare and Smith & Nephew, along with regional distributors offering similar products, can be seen.. 

Scene 18

Notable competitors across categories include:
 - DFU Care: Johnson & Johnson, Smith & Nephew, Mölnlycke Health Care
 - CGMS: Abbott (Freestyle Libre), Medtronic (Guardian), Dexcom
 - Wound Care Plasters: 3M Healthcare, Smith & Nephew, regional distributors

[Audio] The market opportunity in KSA is substantial, with over six point one two million people affected by diabetes, and the prevalence expected to rise. This presents a growing demand for DFU solutions and real-time glucose monitoring technology. Our analysis reveals three key market segments for each product. Firstly, LYTONIC Plus & Gel for DFU is projected to generate four hundred and fifty million Saudi Riyals annually, with a ten percent expected growth rate. Secondly, Wound Care Plaster for DFU is anticipated to reach two hundred million Saudi Riyals, driven by increasing demand for non-invasive solutions. Lastly, Gluco-Sensor 24h CGMS Continuous Glucose Monitoring System is expected to expand significantly, reaching five hundred million Saudi Riyals, due to the heightened demand for diabetes management technology.. 

Scene 19

A. Diabetes in Saudi Arabia:
 - 6.12 million people affected by diabetes, with prevalence expected to rise. - Rising demand for DFU solutions and real-time glucose monitoring technology.
 B. Key Market Segments for Each Product: 1- LYTONIC Plus & Gel for DFU: 450 million SAR with 10% expected growth annually.
 2- Wound Care Plaster for DFU: 200 million SAR with increasing demand for non-invasive solutions.
 3- Gluco-Sensor 24h CGMS Continuous Glucose Monitoring System: 500 million SAR, with significant expansion due to heightened demand for diabetes management technology.

[Audio] The initial investment required for each product line includes regulatory approvals and marketing efforts. This investment enables us to establish a strong presence in the KSA market. The amounts needed are $1.5 million for LYTONIC, $1 million for Wound Care Plaster, and $2 million for Gluco-Sensor 24h.. 

Scene 20

Note: Partnership with Dallah would help facilitate local regulatory requirements and distribution network setup.

A strategic investment is required for each product line, including regulatory approvals and marketing.
- Initial Investment for LYTONIC: $1.5 million (5.6 million SAR)
- Initial Investment for Wound Care Plaster: $1 million (3.75 million SAR)
- Initial Investment for Gluco-Sensor 24h: $2 million (7.5 million SAR)

[Audio] The initial investment required for this strategic partnership opportunity is substantial, but it will yield significant returns. The initial investment needed for each product varies greatly, ranging from 3.75 million SAR for Wound Care Plaster to 7.5 million SAR for Gluco-Sensor 24h CGMS. These figures demonstrate the varying levels of investment required for each product. With an initial investment of 5.6 million SAR for LYTONIC Gel & Cap., we can expect a strong return on investment. Similarly, the investment of 7.5 million SAR for Gluco-Sensor 24h CGMS will also generate substantial profits. As we move forward with setting up this partnership, it is essential to carefully consider these initial investment requirements and plan accordingly.. 

Scene 21

Intial Inv. / million SAR LYTONIC Gel & Cap. Wound Care Plaster Gluco-Sensor 24h CGMS  G.T. 5.6 3.75 7.5 16.850000000000001

PRODUCT Intial Inv. / million SAR LYTONIC Gel & Cap.  SAR                    5.60  Wound Care Plaster  SAR                    3.75  Gluco-Sensor 24h CGMS   SAR                    7.50  G.T.  SAR                  16.85

[Audio] Our financial projections show that each product will generate considerable revenue over the next five years. LYTONIC Plus and Gel are expected to yield SAR 20 million annually, with a net profit margin of 25 percent. The Wound Care Plaster is forecasted to generate SAR 11 million in annual revenue, with a net profit margin of 20 percent. Meanwhile, the Gluco-Sensor 24h is anticipated to produce SAR 26 million in annual revenue, with a net profit margin of 30 percent. These figures illustrate the potential for substantial returns on investment across our product portfolio.. 

Scene 22

Projected Financials for Each Product (5 Years)

Projected Revenue & Net Profit: - LYTONIC: Expected revenue of SAR 20 million per year; net profit 25%. - Wound Care Plaster: Expected revenue of SAR 11 million per year; net profit 20%. - Gluco-Sensor 24h: Expected revenue of SAR 26 million per year; net profit 30%.

[Audio] The analysis reveals that each product has a unique payback period. The LYTONIC Plus and Gel require approximately three years to recoup their initial investment. Meanwhile, the Wound Care Plaster needs around three and a half years to break even. On the other hand, the Gluco-Sensor 24h boasts a relatively shorter payback period of two and a half years. This information will be crucial in determining the most effective allocation of resources and identifying opportunities for growth within the Saudi Arabian market.. 

Scene 23

Payback period for each product investment: - LYTONIC: Estimated 3 years - Wound Care Plaster: Estimated 3.5 years - Gluco-Sensor 24h: Estimated 2.5 years

[Audio] The financial overview of this strategic partnership reveals a promising future. With a total projected revenue of seventy-five million dollars over five years, we can expect significant returns on our investment. Moreover, with a net profit margin of twenty-five percent, we will not only break even but also generate substantial profits. The cumulative payback period for all products is approximately three years, indicating a quick return on investment. This financial performance underscores the potential of our partnership to drive growth and profitability in the KSA market.. 

Scene 24

Combined Revenue and Profitability: - Total projected revenue after 5 years: $75 million - Total net profit: 25% on combined investment - Cumulative payback period for all products: Approx. 3 years

[Audio] The financial projections show that each product will generate substantial revenue over the next five years. LYTONIC Gel and Capsule, Wound Care Plaster, and Gluco-Sensor 24h CGMS are expected to bring in millions of Saudi Riyals annually. The net profit margins range between 20% and 30%, indicating a strong potential for returns on investment. Moreover, the payback periods for each product range from approximately two to three years, suggesting a relatively quick return on investment. These figures imply that the strategic partnership has the potential to yield considerable financial gains.. 

Scene 25

Projected Financials for Each Product (5 Years)& Payback Period Analysis

Expected Revenue (SAR) million SAR/Year  LYTONIC Gel & Cap. Wound Care Plaster Gluco-Sensor 24h CGMS  G.T. 20 11 26 57

PRODUCT Expected Revenue (SAR) million SAR/Year  Net Profit (%)  Payback period LYTONIC Gel & Cap.  SAR             20.00  25% 3.00 Wound Care Plaster  SAR             11.00  20% 3.50 Gluco-Sensor 24h CGMS   SAR             26.00  30% 2.50 G.T.  SAR             57.00  25% 3.00

[Audio] The partnership between Bochéry and Dallah Healthcare provides substantial advantages for both parties, encompassing expanded market presence, better patient outcomes, and elevated brand recognition. To introduce our products in the KSA market, we must ratify the partnership terms, submit regulatory documents, conduct product trials tailored to the local market, execute joint marketing initiatives, and set up distribution networks via Dallah's vast healthcare network. Through collaborative efforts, we can deliver cutting-edge solutions to patients and healthcare professionals, ultimately enhancing the standard of care in the region.. 

Scene 26

Emphasize the partnership's mutual benefits and outline the next steps for launching in KSA. Approval of partnership terms. Regulatory filings and market-specific product trials. Deployment of joint marketing campaigns. Setup distribution channels through Dallah’s healthcare network.

[image] Gluco Sensor 24h
from Bochéry
V.ow BocPfO
Cinco sqp

[Audio] We aim to serve 50% of the estimated 100000 DFU patients in the Kingdom of Saudi Arabia, which translates to 50000 patients who will benefit from our LYTONIC Plus and Gel, Wound Care Plaster, and Gluco-Sensor 24h products. With an expected annual population of 4000000 people suffering from diabetes, we anticipate serving approximately 11000 patients daily. Our goal is to provide timely and effective treatment options to these patients, thereby reducing the risk of limb amputation. By achieving this target, we hope to make a significant impact on the lives of those affected by diabetes.. 

Scene 27

Determine of our target to serve DFU patient

Determine of our target to serve DFU patient

 cases of limb amputation every day due to diabetes in Saudi Arabia in Days Our Target

 50%
 11 6 Expected DMP in  KSA acccording to last estatictics Annual/Population  
               4,000,000    Expected DFUP in  KSA acccording to last estatictics Annual/Population 10%
               1,000,000          100,000  G.T.  Annual target to serve DFU patient
         100,006

[Audio] To determine our target to serve diabetic foot ulcer patients, we need to calculate the cost component per patient. Based on our analysis, we can see that the cost forecast for one patient is approximately SAR 184,800. This includes the costs of LYTONIC Plus, LYTONIC Gel, and wound care products. Our target is to serve 1% of the total DFU patients in the Kingdom of Saudi Arabia, which is approximately 10000 patients. The estimated cost for serving this target is SAR 1,848000000. With an estimated profit margin of 20%, we expect to generate SAR 369,600000 in profits.. 

Scene 28

Calculation for cost Component /  DFU patients and Estimated Profit Margin


 LYTONIC Plus 60 Cap. Dosage  Number of Consumed Packs/ one month Number of Consumed Packs/ Year  SAR                                         500.00  Twice Daily 2 24 LYTONIC Gel Dosage   
  SAR                                         300.00  Twice Daily 8 96 Wound Care products Dosage   
  SAR                                         200.00  Twice Daily 60 720 Cost Forecast / one DFU Patient BY SAR
  SAR                                                                 184,800 
 Target 1 % from  total DFU Patient (1000,000 Patients)
 10,000
 Cost Forecast / Target DFU Patient BY SAR
  SAR                                                     1,848,000,000 
 Estimated Profit Margin 20%
  SAR                                                         369,600,000

[Audio] The references provided will serve as valuable resources for staying updated on the latest developments and trends in the field of diabetes research and treatment. The Saudi Health Council's annual reports will give insight into the current state of diabetes in the Kingdom, while the World Health Organization's global data will provide a broader perspective on the disease's impact worldwide. Additionally, the International Journal of Diabetes Research will offer cutting-edge information on new treatments and technologies. By referencing these sources, we can ensure that our partnership remains informed and effective in addressing the needs of patients suffering from diabetic foot ulcers in the KSA market. 

Scene 29

• Source 1: Saudi Health Council, Annual Diabetes Reports (2024). • Source 2: WHO Global Diabetes Data (2023). • Source 3: International Journal of Diabetes Research (2024).

[Audio] We have concluded this presentation and would like to express our gratitude to everyone who has attended and engaged with us throughout. We believe that our partnership will lead to significant advancements in the treatment and care of diabetic foot ulcers in Saudi Arabia. With our products LYTONIC Plus, Gel, Wound Care Plaster, and Gluco-Sensor 24h, we are confident that we can positively impact the lives of those affected by diabetes. Thank you for your time, and we look forward to collaborating to shape the future of diabetic care in KSA.. 

Scene 30

Bochéry & Dallah Healthcare
A Strategic Alliance for Saudi Arabia’s Future in Diabetic Care

Changing the Perspective on Diabetic Foot  Ulcer Treatment And Wound Care

The population of Saudi Arabia is approximately 34 million people, with a growing demand for healthcare services. This demographic trend presents a significant opportunity for pharmaceutical companies like ours to expand their presence in the region. With a large and young population, there is a pressing need for innovative solutions to address the rising incidence of chronic diseases such as diabetes.

avatar

The objective of this partnership is clear: to form a strategic alliance between Bochéry and Dallah Healthcare to bring innovative healthcare solutions to the Kingdom of Saudi Arabia. By combining our strengths, we aim to address the unmet needs in diabetic foot ulcer care and diabetes monitoring. Our ultimate goal is to establish a successful partnership that delivers cutting edge diabetic care solutions to the K-S-A market, leveraging Dallah's local expertise and Bochéry's advanced healthcare products

The population of Saudi Arabia has consistently grown over the years, reaching approximately 34 million people as of 2024. Advancements in healthcare, a younger demographic structure, and the influx of foreign workers drawn by the country's expanding economic opportunities under Saudi Vision 2030 contributed to this growth.

Saudi Arabia has a large population of approximately 34 million people, with over 18% of them suffering from diabetes. This translates to around 6.12 million individuals living with diabetes. Furthermore, it's estimated that between 15% to 25% of these diabetic patients develop diabetic foot ulcers, resulting in a minimum of 918000 to a maximum of 1530000 individuals affected. On average, this would mean that around 1.22 million people suffer from diabetic foot ulcers.

In Saudi Arabia, it's estimated that approximately 6.5 million individuals will have diabetes by 2024. This staggering figure is expected to rise to 8 million by 2029, driven by population growth and aging. Unfortunately, this surge in diabetes cases comes with a significant risk of Diabetic Foot Ulcers (D-F-U--), which can lead to amputations. In fact, it's predicted that there will be a 20% increase in amputations over the next five years. This alarming trend highlights the urgent need for effective solutions to prevent and treat D-F-U-.

The risks associated with diabetic foot ulcers are quite alarming. Between 15 and 25 percent of individuals with diabetes will develop these ulcers during their lifetime, highlighting the importance of prevention and early detection. The main risk factors include neuropathy, poor glycemic control, peripheral arterial disease, and a history of previous foot ulcers, which can significantly increase the likelihood of developing a D-F-U--. The mortality rate for patients with D-F-U's is approximately 18.5%, nearly double that of patients without D-F-U-s-, and amputations can lead to even higher mortality rates, reaching as high as 32.2%.

In Saudi Arabia, it is estimated that between five percent to fifteen percent of diabetic patients with diabetic foot ulcers may require amputations. This translates to over three thousand diabetic related amputations occurring annually. Furthermore, the data shows that men are disproportionately affected, with amputation and mortality rates significantly higher among males, ranging from seventy six percent to seventy eight percent.

Approximately 6.5 million individuals will have diabetes in Saudi Arabia by 2024, according to the data. This number is expected to rise to 8 million by 2029. Moreover, the rate of diabetic foot ulcers is increasing proportionally. Additionally, the forecast estimates a 20% increase in amputations due to population growth and aging.

The risks associated with diabetic foot are numerous and can have significant consequences on a person's quality of life. Ulcers and wounds can develop due to poor circulation and increased infection risk, leading to delayed healing. This can also increase the risk of bacterial infections, which can spread quickly and affect bones and tissues. In advanced cases, amputation may be necessary to prevent the spread of infection. Moreover, the psychological and social impact of losing a limb can be devastating, affecting one's ability to maintain independence and participate in daily activities. Furthermore, the high costs associated with treating diabetic foot can place a significant burden on healthcare systems.

The estimated healthcare costs for diabetic foot in Saudi Arabia are substantial. The annual treatment cost per patient ranges between SAR 40000 and SAR 80000. This translates into significant expenses when considering the total annual cost for all patients. For 918000 patients, the estimated cost would be approximately SAR 55 billion. Alternatively, with 1530000 patients, the estimated cost would be around SAR 91.8 billion. On average, with 1244000 patients, the estimated cost would be approximately SAR 73.4 billion.

The high costs associated with diabetic foot ulcer treatment can be attributed to several factors. Specialized medical teams are required to treat these complex conditions, which increases the overall cost. Advanced surgeries, including amputations, may be necessary in severe cases, contributing to the high expenses. Medical equipment such as prosthetics and physiotherapy tools are often needed, adding to the overall cost. Extended hospital stays are common due to the severity of the conditions, resulting in higher healthcare expenditures. Chronic complications like systemic infections can arise, leading to increased healthcare costs.

Prevention is crucial in addressing the challenges posed by diabetic foot ulcers. Educating the public and at risk individuals about the importance of proper foot care can prevent the onset of these debilitating conditions. Better management and monitoring of diabetic patients can help identify potential issues early on, thereby preventing the escalation of the disease. Detecting and managing mild cases promptly can also prevent the progression of the condition. Prioritizing prevention can reduce the burden of diabetic foot ulcers on individuals, families, and society as a whole.

In Saudi Arabia, there are numerous medical centers and hospitals providing diabetic foot care services. Over 500 government and private hospitals offer specialized services for diabetic foot patients. More than 50 specialized diabetes centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. Many hospitals also have specialized units or departments dedicated to diabetic foot care. Hundreds of outpatient clinics provide diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable facilities in this field include King Faisal Specialist Hospital & Research Center, National Guard Health Affairs Hospitals, Dallah Hospital Group, Dr  Sulaiman Al Habib Hospitals, and Diabetes Centers affiliated with the Ministry of Health across various regions.

The pharmaceutical market in Saudi Arabia has shown remarkable growth over the years, driven primarily by the country's large population and increasing awareness about health issues. The current market value stands at approximately 45 billion Saudi Riyals, with a projected annual growth rate of 8%. This presents a significant opportunity for companies looking to expand their presence in the region. In particular, the market for diabetes related treatments has seen substantial growth, driven by the rising prevalence of diabetes among the local population. With over 6.12 million people affected by diabetes, Saudi Arabia ranks among the top countries globally in terms of diabetes prevalence. This trend is expected to continue, with the World Health Organization predicting a further increase in the number of diabetes cases in the coming years. As a result, there is a growing demand for innovative and effective treatments for diabetes, including devices such as continuous glucose monitors and wound care products. Companies that can provide these solutions will be well positioned to capitalize on this growing market.

The pharmaceutical industry in Saudi Arabia has experienced significant growth over the past few years, with a current market value of SAR 44 billion, equivalent to USD 11.72 billion in 2022. This impressive figure is expected to continue growing, reaching SAR 56.6 billion, or approximately USD 15.09 billion, by 2027. With a compound annual growth rate of 5.2%, this market presents a promising opportunity for companies looking to expand their presence in the region.

The companies involved in this strategic partnership opportunity are Jamjoom Pharma, Avalon Pharma, Tabuk Pharmaceuticals, and SPIMACO, which are prominent pharmaceutical organizations with a strong presence in the Kingdom of Saudi Arabia, focusing on providing high quality treatments to patients.

In the K-S-A market, notable competitors across various categories can be found. Key players in the area of D-F-U care include Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care, which offer products such as wound dressings and negative pressure wound therapy devices. Prominent competitors in the category of continuous glucose monitoring systems are Abbott with their Freestyle Libre product, Medtronic with their Guardian system, and Dexcom. Additionally, in the field of wound care plasters, major players like 3M Healthcare and Smith & Nephew, along with regional distributors offering similar products, can be seen.

The market opportunity in K-S-A is substantial, with over six point one two million people affected by diabetes, and the prevalence expected to rise. This presents a growing demand for D-F-U solutions and real time glucose monitoring technology. Our analysis reveals three key market segments for each product. Firstly, LYTONIC Plus & Gel for D-F-U is projected to generate four hundred and fifty million Saudi Riyals annually, with a ten percent expected growth rate. Secondly, Wound Care Plaster for D-F-U is anticipated to reach two hundred million Saudi Riyals, driven by increasing demand for non invasive solutions. Lastly, Gluco Sensor 24 hours C-G-M-S Continuous Glucose Monitoring System is expected to expand significantly, reaching five hundred million Saudi Riyals, due to the heightened demand for diabetes management technology.

The initial investment required for each product line includes regulatory approvals and marketing efforts. This investment enables us to establish a strong presence in the K-S-A market. The amounts needed are 1 point 5  million dollars for LYTONIC, 1  million dollars for Wound Care Plaster, and 2  million dollars for Gluco Sensor 24 hours.

The initial investment required for this strategic partnership opportunity is substantial, but it will yield significant returns. The initial investment needed for each product varies greatly, ranging from 3.75 million S-A-R for Wound Care Plaster to 7.5 million S-A-R for Gluco Sensor 24 hours C-G-M-S-. These figures demonstrate the varying levels of investment required for each product. With an initial investment of 5.6 million S-A-R for LYTONIC Gel & Cap., we can expect a strong return on investment. Similarly, the investment of 7.5 million S-A-R for Gluco Sensor 24 hours C-G-M-S will also generate substantial profits. As we move forward with setting up this partnership, it is essential to carefully consider these initial investment requirements and plan accordingly.

Our financial projections show that each product will generate considerable revenue over the next five years. LYTONIC Plus and Gel are expected to yield SAR 20 million annually, with a net profit margin of 25 percent. The Wound Care Plaster is forecasted to generate SAR 11 million in annual revenue, with a net profit margin of 20 percent. Meanwhile, the Gluco Sensor 24 hours is anticipated to produce SAR 26 million in annual revenue, with a net profit margin of 30 percent. These figures illustrate the potential for substantial returns on investment across our product portfolio.

The analysis reveals that each product has a unique payback period. The LYTONIC Plus and Gel require approximately three years to recoup their initial investment. Meanwhile, the Wound Care Plaster needs around three and a half years to break even. On the other hand, the Gluco Sensor 24 hours boasts a relatively shorter payback period of two and a half years. This information will be crucial in determining the most effective allocation of resources and identifying opportunities for growth within the Saudi Arabian market.

The financial overview of this strategic partnership reveals a promising future. With a total projected revenue of seventy five million dollars over five years, we can expect significant returns on our investment. Moreover, with a net profit margin of twenty five percent, we will not only break even but also generate substantial profits. The cumulative payback period for all products is approximately three years, indicating a quick return on investment. This financial performance underscores the potential of our partnership to drive growth and profitability in the K-S-A market.

The financial projections show that each product will generate substantial revenue over the next five years. LYTONIC Gel and Capsule, Wound Care Plaster, and Gluco Sensor 24 hours C-G-M-S are expected to bring in millions of Saudi Riyals annually. The net profit margins range between 20% and 30%, indicating a strong potential for returns on investment. Moreover, the payback periods for each product range from approximately two to three years, suggesting a relatively quick return on investment. These figures imply that the strategic partnership has the potential to yield considerable financial gains.

The partnership between Bochéry and Dallah Healthcare provides substantial advantages for both parties, encompassing expanded market presence, better patient outcomes, and elevated brand recognition. To introduce our products in the K-S-A market, we must ratify the partnership terms, submit regulatory documents, conduct product trials tailored to the local market, execute joint marketing initiatives, and set up distribution networks via Dallah's vast healthcare network. Through collaborative efforts, we can deliver cutting edge solutions to patients and healthcare professionals, ultimately enhancing the standard of care in the region.

We aim to serve 50% of the estimated 100000 D-F-U patients in the Kingdom of Saudi Arabia, which translates to 50000 patients who will benefit from our LYTONIC Plus and Gel, Wound Care Plaster, and Gluco Sensor 24 hours products. With an expected annual population of 4000000 people suffering from diabetes, we anticipate serving approximately 11000 patients daily. Our goal is to provide timely and effective treatment options to these patients, thereby reducing the risk of limb amputation. By achieving this target, we hope to make a significant impact on the lives of those affected by diabetes.

To determine our target to serve diabetic foot ulcer patients, we need to calculate the cost component per patient. Based on our analysis, we can see that the cost forecast for one patient is approximately SAR 184800. This includes the costs of LYTONIC Plus, LYTONIC Gel, and wound care products. Our target is to serve 1% of the total D-F-U patients in the Kingdom of Saudi Arabia, which is approximately 10000 patients. The estimated cost for serving this target is S-A-R 1848000000. With an estimated profit margin of 20%, we expect to generate SAR 369600000 in profits.

The references provided will serve as valuable resources for staying updated on the latest developments and trends in the field of diabetes research and treatment. The Saudi Health Council's annual reports will give insight into the current state of diabetes in the Kingdom, while the World Health Organization's global data will provide a broader perspective on the disease's impact worldwide. Additionally, the International Journal of Diabetes Research will offer cutting edge information on new treatments and technologies. By referencing these sources, we can ensure that our partnership remains informed and effective in addressing the needs of patients suffering from diabetic foot ulcers in the K-S-A market

We have concluded this presentation and would like to express our gratitude to everyone who has attended and engaged with us throughout. We believe that our partnership will lead to significant advancements in the treatment and care of diabetic foot ulcers in Saudi Arabia. With our products LYTONIC Plus, Gel, Wound Care Plaster, and Gluco Sensor 24 hours, we are confident that we can positively impact the lives of those affected by diabetes. Thank you for your time, and we look forward to collaborating to shape the future of diabetic care in K-S-A-.